Business
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 15, 2026, at 10:30 a.m. PT.
About this update from Adc Therapeutics Sa
[{"type":"text","content":"LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 15, 2026, at 10:30 a.m. PT.","length":376,"tagName":"p"},{"type":"image","alt":"ADC Therapeutics logo (PRNewsfoto/ADC Therapeutics SA)","displaySize":"","headline":null,"caption":"ADC Therapeutics logo (PRNewsfoto/ADC Therapeutics SA)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":250,"url":"https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xnw4DzeStakBHZIZhIV_hA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ0MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7","width":400,"height":250}},"href":"https://mma.prnewswire.com/media/2543351/ADC_Therapeutics_SA__logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.","length":244,"tagName":"p"},{"type":"text","content":"About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.","length":298,"tagName":"p"},{"type":"text","content":"ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic...